NFKB1 and plasma cell myeloma: Interestingly, recent reports indicate that there is a paradigm shift in myeloma with respect to ascribing the mechanism of Bortezomib's anti-tumor activity to NF-κB inhibition [53], and suggest that Bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-κB activity [54].